Trial Profile
Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Bayer
- 03 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Mar 2013 Planned end date changed from 1 Mar 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov.